HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors

被引：0
作者：
Deblock, M. [1 ]
Esterni, B. [1 ]
Tarpin, C. [1 ]
Charaffe-Jauffret, E. [1 ]
Extra, J. M. [1 ]
Viens, P. [1 ]
Goncalves, A. [1 ]
机构：
[1] Inst Paoli Calmettes, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1105
引用
收藏
页数：1
相关论文
共 50 条
[41]   Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment [J].
Salimbeni, Beatrice Taurelli ;
Giudici, Fabiola ;
Pescia, Carlo ;
Giachetti, Pier Paolo Maria Berton ;
Scafetta, Roberta ;
Zagami, Paola ;
Marra, Antonio ;
Trapani, Dario ;
Esposito, Angela ;
Scagnoli, Simone ;
Cerbelli, Bruna ;
Botticelli, Andrea ;
Munzone, Elisabetta ;
Fusco, Nicola ;
Criscitiello, Carmen ;
Curigliano, Giuseppe .
NPJ BREAST CANCER, 2025, 11 (01)
[42]   Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study [J].
Schrader, Iris ;
Foerster, Frank Gerhard ;
Schneeweiss, Andreas ;
Geberth, Matthias ;
Hahn, Lars ;
Schumacher, Claudia ;
Hertz-Eichenrode, Martin Michael ;
Schoenegg, Winfried ;
Wolfgarten, Matthias Kim ;
Kutscheidt, Andreas ;
Schmidt, Marcus ;
Aktas, Bahriye .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[43]   Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer [J].
He, Kewen ;
Wang, Xinzhao ;
Guan, Xiyun ;
Yu, Qian ;
Ma, Qinghua ;
Liu, Zhaoyun ;
Yu, Zhiyong .
ANTICANCER RESEARCH, 2017, 37 (10) :5647-5653
[44]   Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer [J].
Lv, Huimin ;
Yan, Min ;
Zhang, Mengwei ;
Niu, Limin ;
Zeng, Huiai ;
Sun, Huihui ;
Zhao, Shengnan ;
Wang, Jing .
CANCER RESEARCH, 2024, 84 (09)
[45]   Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer [J].
Bilici, Ahmet ;
Selcukbiricik, Fatih ;
Demir, Nazan ;
Ustaalioglu, Bala Basak Oven ;
Dikilitas, Mustafa ;
Yildiz, Ozcan .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (20) :8661-8666
[46]   Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC) [J].
Gluck, S. ;
Lobo, C. ;
Reis, I. ;
Lopes, G. ;
Carmody, C. ;
Tukia, K. ;
Hurley, J. ;
Seo, P. ;
Silva, O. ;
Slingerland, J. ;
Welsh, C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[47]   New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting [J].
Cannita, Katia ;
Paradisi, Stefania ;
Cocciolone, Valentina ;
Bafile, Alberto ;
Rinaldi, Lucia ;
Irelli, Azzurra ;
Baldi, Paola Lanfiuti ;
Zugaro, Luigi ;
Manetta, Rosa ;
Alesse, Edoardo ;
Ricevuto, Enrico ;
Ficorella, Corrado .
CANCER MEDICINE, 2016, 5 (09) :2232-2239
[48]   Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer [J].
Urakci, Zuhat ;
Ebinc, Senar ;
Tunc, Sezai ;
Kalkan, Ziya ;
Oruc, Zeynep ;
Kucukoner, Mehmet ;
Kaplan, Muhammet Ali ;
Isikdogan, Abdurrahman .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
[49]   First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC) [J].
Hoskins, Kent F. ;
Richards, Paul ;
Wisinski, Kari .
CANCER RESEARCH, 2018, 78 (13)
[50]   Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer [J].
De Mattos-Arruda, Leticia ;
Cortes, Javier .
ONCOLOGIST, 2012, 17 (05) :631-644
12345